CH-223191

SKU: orb1305470

Description

CH-223191 is a potent and selective AhR antagonist with an IC50 of 0.03 µM against TCDD-induced activity. It is widely used in research areas including immunology, oncology, and toxicology for in vitro and in vivo studies of inflammation, tumor immunity, and neuroprotection.

Research Area

Immunology & Inflammation, Stem Cell & Developmental Biology

Key Properties

• CAS Number: 301326-22-7
• MW: 333.39
• Purity: >98%
• Formula: C₁₉H₁₉N₅O
• SMILES: Cc1ccccc1\N=N\c1ccc(NC(=O)c2ccnn2C)c(C)c1
• Target: Transcription factor
• Solubility: Soluble in DMSO ( up tol 25 mg/ml) or in Ethanol (up to 10 mg/ml with warming)

Bioactivity

• Target IC50:
  AhR:30 nM
• In Vivo:
  METHODS: To study the preventive toxic effects of CH-223191 on 2,3,7,8-TCDD, CH-223191 (10 mg/kg) was intraperitoneally injected into male ICR mice once a day for 25 consecutive days. RESULTS: C-223191 inhibited the expression of liver cytochrome P450 1A1 and the intracellular fat content in hepatocytes, and reduced the AST and ALT activities in mice treated with TCDD.
• In Vitro:
  METHODS: HepG2 cells were treated with CH-223191 (0.1-10 μM) for 1 hour, and the protein levels were detected by Western Blot method. RESULTS: C-223191 reduces the expression of cytochrome P450 1A1 protein caused by TCDD.

Storage & Handling

• Storage: -20°C
• Expiration Date: 12 months from date of receipt.
• Disclaimer: For research use only

Alternative Names

CH223191, CH-223191, CH 223191, AhR, Aryl Hydrocarbon Receptor, ArylHydrocarbonReceptor, Inhibitor, inhibit

Compound Identifiers

PubChem CID

3091786